Oxidative Stress and Antioxidants in Neurological Diseases: Is There Still Hope?

被引:93
作者
Carvalho, Andreia Neves [1 ,2 ]
Firuzi, Omidreza [3 ]
Gama, Maria Joao [1 ]
van Horssen, Jack [2 ]
Saso, Luciano [4 ]
机构
[1] Univ Lisbon, Fac Pharm, Inst Invest Med iMED ULisboa, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal
[2] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands
[3] Shiraz Univ Med Sci, Med & Nat Prod Chem Res Ctr, Shiraz, Iran
[4] Sapienza Univ Rome, Dept Physiol & Pharmacol Vittorio Erspamer, Rome, Italy
关键词
Alzheimer's disease; antioxidants; biomarkers; huntington's disease; multiple sclerosis; neurodegenerative diseases; oxidative stress; parkinson's disease; CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL COMPLEX-I; MULTIPLE-SCLEROSIS LESIONS; MANGANESE SUPEROXIDE-DISMUTASE; PLACEBO-CONTROLLED PHASE-3; GENERATING NADPH OXIDASES; TRANSCRIPTION FACTOR NRF2; NITRIC-OXIDE SYNTHASE; CUL3-BASED E3 LIGASE; FUMARIC-ACID ESTERS;
D O I
10.2174/1389450117666160401120514
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxidative stress is a pathological feature common to a multitude of neurological diseases. The production of reactive oxygen species (ROS) is the main mechanism underlying this cellular redox imbalance. Antioxidants protect biological targets against ROS, therefore, they have been considered as attractive potential therapeutic agents to counteract ROS-mediated neuronal damage. However, despite encouraging in vitro and preclinical in vivo data, the clinical efficacy of antioxidant treatment strategies is marginal and most clinical trials using antioxidants as therapeutic agents in neurodegenerative diseases have yielded disappointing outcomes. This might in part be due to the need of adjustment in concentrations and time parameters between preclinical studies and clinical settings. Moreover new efficient delivery methods need to be investigated, particularly taking into account that a successful therapeutic agent for neurological diseases should readily cross the blood-brain barrier (BBB). In that sense, the use of compounds that cross the BBB and boost the endogenous antioxidant defense machinery, by activating for instance the Nrf2 pathway, or compounds that are able to modulate ROS production, such as NOX enzyme inhibitors, seems to represent a more promising approach to combat oxidative stress in the central nervous system (CNS). Here we present a brief overview of the main players in oxidative stress and outline evidences of their involvement in Parkinson's disease, Alzheimer's disease, Huntington's disease and multiple sclerosis. Finally, we review and critically discuss the potential of antioxidants as therapeutics for central nervous system disorders with a special focus on emerging novel therapeutic strategies.
引用
收藏
页码:705 / 718
页数:14
相关论文
共 228 条
[41]   Pharmacology and Clinical Drug Candidates in Redox Medicine [J].
Dao, V. Thao-Vi ;
Casas, Ana I. ;
Maghzal, Ghassan J. ;
Seredenina, Tamara ;
Kaludercic, Nina ;
Robledinos-Anton, Natalia ;
Di Lisa, Fabio ;
Stocker, Roland ;
Ghezzi, Pietro ;
Jaquet, Vincent ;
Cuadrado, Antonio ;
Schmidt, Harald H. H. W. .
ANTIOXIDANTS & REDOX SIGNALING, 2015, 23 (14) :1113-1129
[42]   Parkinson's disease: Mechanisms and models [J].
Dauer, W ;
Przedborski, S .
NEURON, 2003, 39 (06) :889-909
[43]   Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease [J].
De Leo, ME ;
Borrello, S ;
Passantino, M ;
Palazzotti, B ;
Mordente, A ;
Daniele, A ;
Filippini, V ;
Galeotti, T ;
Masullo, C .
NEUROSCIENCE LETTERS, 1998, 250 (03) :173-176
[44]   Nrf2-induced antioxidant Protection: A Promising target to counteract ROS-mediated damage in neurodegenerative disease? [J].
de Vries, Helga E. ;
Witte, Maarten ;
Hondius, David ;
Rozermuller, Annemieke J. M. ;
Drukarch, Benjamin ;
Hoozemans, Jeroen ;
van Horssen, Jack .
FREE RADICAL BIOLOGY AND MEDICINE, 2008, 45 (10) :1375-1383
[45]   Drug interaction potential of resveratrol [J].
Detampel, Pascal ;
Beck, Mareike ;
Kraehenbuehl, Stephan ;
Huwyler, Joerg .
DRUG METABOLISM REVIEWS, 2012, 44 (03) :253-265
[46]   INCREASED LEVELS OF LIPID HYDROPEROXIDES IN THE PARKINSONIAN SUBSTANTIA-NIGRA - AN HPLC AND ESR STUDY [J].
DEXTER, DT ;
HOLLEY, AE ;
FLITTER, WD ;
SLATER, TF ;
WELLS, FR ;
DANIEL, SE ;
LEES, AJ ;
JENNER, P ;
MARSDEN, CD .
MOVEMENT DISORDERS, 1994, 9 (01) :92-97
[47]   INCREASED NIGRAL IRON CONTENT AND ALTERATIONS IN OTHER METAL-IONS OCCURRING IN BRAIN IN PARKINSONS-DISEASE [J].
DEXTER, DT ;
WELLS, FR ;
LEES, AJ ;
AGID, F ;
AGID, Y ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1989, 52 (06) :1830-1836
[48]   ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE-METALS IN PARKINSONS-DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA [J].
DEXTER, DT ;
CARAYON, A ;
JAVOYAGID, F ;
AGID, Y ;
WELLS, FR ;
DANIEL, SE ;
LEES, AJ ;
JENNER, P ;
MARSDEN, CD .
BRAIN, 1991, 114 :1953-1975
[49]   BASAL LIPID-PEROXIDATION IN SUBSTANTIA NIGRA IS INCREASED IN PARKINSONS-DISEASE [J].
DEXTER, DT ;
CARTER, CJ ;
WELLS, FR ;
JAVOYAGID, F ;
AGID, Y ;
LEES, A ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1989, 52 (02) :381-389
[50]   Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain [J].
DiFiglia, M ;
Sapp, E ;
Chase, KO ;
Davies, SW ;
Bates, GP ;
Vonsattel, JP ;
Aronin, N .
SCIENCE, 1997, 277 (5334) :1990-1993